Therefore, considering the broad impact of depression and the marked limitations of the existing antidepressants, identifying the key brain regions and molecular targets that mediate leptin's antidepressant action may provide new insights into the pathogenesis of depression and the development of novel therapeutic strategies for the treatment of this illness. The gene discussed is LEP; the disease is depressive symptom measurement.